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ABSTRACT
The Bcl-2 protein has an anti-apoptotic effect in
neuronal and other cell types. We show for the first
time that the Bcl-2 promoter is activated by the
neuronal survival factor nerve growth factor (NGF) and
that this effect is dependent on a region of the
promoter from –1472 to –1414. This activation requires
the Rap-1 G protein and the MEK-1 and p42/p44 MAPK
enzymes but is independent of other NGF-activated
signalling pathways involving protein kinase A or
protein kinase C.
INTRODUCTION
The process of programmed cell death (apoptosis) plays a key
role in the development and functioning of a number of different
organ systems such as the immune system and the nervous system
and alterations in the amount of such cell death have been
implicated in a number of different human diseases including
autoimmune diseases and neurodegenerative diseases (reviewed
in 1). The Bcl-2 protein has been shown to play a key role in the
regulation of programmed cell death, being able to protect a wide
variety of cell types, including B cells and neuronal cells, from
apoptosis (reviewed in 2,3). In neuronal cells, for example,
overexpression of Bcl-2 has been shown to enhance the survival
of both central and peripheral nervous system neurons in culture
as well as counteract the effects of a variety of apoptotic stimuli
such as the withdrawal of neurotrophic factors (4,5). Similarly,
overexpression of Bcl-2 in transgenic animals protects neurons
from cell death during development, resulting in animals with
increased numbers of neurons and also protects neurons in the
adult from axotomy-induced cell death (6,7).
As well as being protected by overexpression of Bcl-2, it is
clear that normal levels of Bcl-2 expression in neuronal cells play
a key role in their survival during normal development when a
high proportion of the neuronal cells which initially form,
normally die by apoptosis (8). Thus, the inactivation of the Bcl-2
gene in knock-out mice results in losses of motor neurons,
sympathetic and sensory neurons (9) and also impaired survival
in cultured neurons derived from such mice (10). Similarly,
reduction of Bcl-2 levels in cultured neurons using an anti-sense
approach inhibits the enhanced survival normally observed on
adding neurotrophic factors (11).
Therefore, overexpression of Bcl-2 results in enhanced neuronal
survival even in the absence of neurotrophic factors whilst in its
absence, neurons die even in the presence of such survival factors.
It is, therefore, of great interest that treatment with the neurotrophic
factor, nerve growth factor (NGF), has been shown to greatly
enhance the level of Bcl-2 expression in mast cells (12),
melanocytes (13) and the PC12 phaeochromocytoma cell line
(14) which resembles sympathetic neurons and in cerebellar
granule neurons (15). Moreover, the artificial overexpression of
Bcl-2 in PC12 cells results in enhanced survival following NGF
withdrawal (16) and, conversely, inhibiting the rise in Bcl-2
levels induced by NGF in melanocytes or PC12 cells prevents the
normal anti-apoptotic effect of NGF treatment in these cells
(13,14). Hence the protective effect of NGF treatment is
dependent upon NGF-induced up regulation of Bcl-2.
These experiments suggest, therefore, a model in which NGF
produces its effect on the survival of neuronal cells in the
developing and adult nervous system, at least in part, via the
stimulation of Bcl-2 expression. It is thus of critical importance
to elucidate the mechanisms/signalling pathways by which such
effects on Bcl-2 expression are achieved. Despite this and the
intense attention devoted to the function of the Bcl-2 protein,
relatively little work has been done on the mechanisms regulating
bcl-2 gene expression. Thus, some reports have appeared
describing regulatory elements in the Bcl-2 promoter which regulate
its expression in specific non-neuronal cell types (e.g. 17–20) and
we have recently shown that the POU family transcription factor
Brn-3a can activate the Bcl-2 promoter in neuronal cells resulting
in a protective effect against apoptosis (21,22). However, no
study has investigated the manner in which NGF activates Bcl-2
expression. Therefore, we have carried out a study aimed at
directly investigating whether NGF can activate the Bcl-2
promoter and determining the mechanisms/signalling pathways
by which it mediates this effect.
MATERIALS AND METHODS
Materials
2.5S NGF was obtained from Sigma. The specific MAPK
inhibitors PD98059 (p42/p44) and SB203580 (p38) were from
NEB and Calbiochem, respectively, and were used at concentrations
of 50 and 10 mM, respectively. Cell culture media and serum were
from Gibco BRL.
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Plasmid DNA
Bcl-2 promoter–reporter constructs containing various regions of
the Bcl-2 promoter linked to the luciferase reporter gene have
previously been described (17,20–22). The expression vectors
for the constitutively active p42/p44 MEK-1 mutant (SS/DD) and
the dominant negative p42/p44 MAPK mutants (MAPKTA and
MAPKYF) were a kind gift of Dr J. Pouyssegur (23). The
expression plasmid containing the constitutively active subunit of
PKC delta was a kind gift of Dr M. Marber and Dr P. Parker.
The PKI and constitutively active PKA vectors were a kind gift
of Dr R. Maurer whilst the Rap-1 N17 construct was a kind gift
of Dr P. J. Stork.
Cell culture and transfections
PC12 cells (24) were maintained in L15 medium supplemented
with 10% (v/v) FCS and 1 mM glutamine. Transient transfections
of PC12 cells were performed using the calcium phosphate
procedure as described by Gorman (25). Transfections were
carried out with 4 ×105 cells/well on 6-well tissue culture plates.
For each transfection, a b-galactosidase expression plasmid was
used as an internal control. Following calcium phosphate
transfections, PC12 cells were glycerol-shocked and incubated
for 16 h in media containing 1% horse serum. Cells were then
treated with 2.5S NGF for 30 h. In some experiments, cells were
pre-treated with appropriate kinase inhibitor for 1 h before
addition of NGF. Cells were then harvested and assayed for
luciferase activity according to the manufacturer’s instructions
(Promega). Results were normalised to b-galactosidase activity
and by using relative protein content as determined by the
Bradford protein assay (26).
RESULTS
Although treatment of PC12 cells with NGF has been shown to
result in enhanced levels of Bcl-2 protein (14), no previous study
had demonstrated a direct effect of NGF on the Bcl-2 promoter.
We therefore transfected PC12 cells with a construct containing
the 3934 bases upstream of the translational start site of the bcl-2
gene linked to a luciferase reporter gene (17,20; Fig. 1). As shown
in Figure 2, this construct (LB322) was ~6-fold inducible by
NGF. To map the site of NGF responsiveness, we carried out
similar experiments with several deletion constructs containing
progressively less extensive upstream regions of the Bcl-2
promoter. In these experiments (Fig. 2) the construct containing
1642 bases of upstream sequence (LB329) was inducible by NGF
to a similar extent to the full-length promoter whereas one
containing 1281 bases (LB335) was virtually uninducible. This
indicates that promoter elements between bases –1642 and –1281
are essential for inducibility of the Bcl-2 promoter by NGF.
Interestingly, this region contains a cyclic AMP response
element (CRE) located between bases 1546 and 1537 which is
involved in the induction of Bcl-2 expression during B-cell
activation. It has previously been shown the CRE motifs in the
c-fos (27) and calcitonin gene related peptide (28) promoters are
involved in their inducibility by NGF. We therefore tested
whether a construct containing a mutated CRE within the Bcl-2
promoter was impaired in its response to NGF. However, this
construct (MUCRE) was as inducible by NGF as the corresponding
promoter containing an intact CRE (LB334; Fig. 1). Moreover,
none of the Bcl-2 promoter constructs showed a response to
Figure 1. Structure of the Bcl-2 promoter constructs used in this study.
Figure 2. Activation of various Bcl-2 promoter constructs (see Fig. 1) by NGF.
In all cases, promoter activity in the presence of NGF is compared to that of the
same construct in the absence of NGF (set at 100%). Values are the mean of five
experiments whose standard error is shown by the bars. MuCRE indicates the
result with the LB334 construct further modified by mutation of the AMP CRE.
treatment of the PC12 cells with cyclic AMP (data not shown)
indicating that the CRE in the Bcl-2 promoter does not function
to produce a response to NGF or cyclic AMP in PC12 cells.
Having established that the region from –1642 to –1281 bases
was involved in NGF inducibility but that this effect did not
involve the CRE, we wished to map this NGF response element
further. It has previously been demonstrated that Bcl-2 has two
promoters, an upstream P1 promoter and a downstream P2
promoter which is located entirely downstream of base –1280.
Therefore, to more precisely map the NGF element, we used a
series of constructs (Fig. 1) containing only the P1 promoter
upstream of base –1280 linked to progressively shorter regions of
upstream sequence. In these experiments (Fig. 3) a construct
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Figure 3. Activation of various Bcl-2 promoter constructs (see Fig. 1) by NGF.
In all cases, promoter activity in the presence of NGF is compared to that of the
same construct in the absence of NGF (set at 100%). Values are the mean of five
experiments whose standard error is shown by the bars.
inducible by NGF in PC12 cells confirming that this effect could
be demonstrated for the isolated P1 promoter. In a deletion
analysis of this promoter (Fig. 3) NGF inducibility was observed
for all constructs down to that which contained the region from
–1472 to –1281 (LB378) but was not observed for the next
shortest construct containing the region from –1414 to –1281
(LB379). This indicates, therefore, that the region from –1472 to
–1414 is critical for the inducibility of the Bcl-2 promoter by
NGF. This region is distinct from, for example, the region which
mediates induction of Bcl-2 during B-cell activation (20) and
from the region of the promoter which we have previously shown
renders it responsive to the POU family transcription factor
Brn-3a (21,22). 
We next wished to study the signalling pathways by which NGF
activates the Bcl-2 promoter. We therefore investigated the effect
of specifically inhibiting or activating various kinase-mediated
signalling pathways upon the activation of the Bcl-2 promoter by
NGF. Thus, it is known that binding of NGF to its receptor
activates the Ras/Raf/MEK/ERK pathway which results in the
activation of the mitogen-activated protein kinases (MAPK) p42
MAPK (ERK2) and p44 MAPK (ERK1) (32,33). To inhibit the
activity of the p42/p44 MAPK enzymes, we used the synthetic
compound PD098059 which has been shown to specifically
inhibit the activation of these kinases by growth factors in vivo
(34). In these experiments (Fig. 4a) the PD compound completely
blocked the activation of the full-length Bcl-2 promoter by NGF
suggesting that the p42/p44 MAPK signalling pathway was
involved in this effect. In contrast, addition of the compound
SB203580 which specifically inhibits the p38 MAPK pathway
has no effect on the activation of the promoter by NGF indicating
that the p38 MAPK pathway was unlikely to be involved and
demonstrating the specific effect of the PD098059 compound. In
neither case did the compounds affect the basal activity of the
Bcl-2 promoter in the absence of NGF (Fig. 4a), indicating that
the effect of PD098059 was specific to NGF induction.
To further demonstrate the involvement of the p42/p44 MAPK
pathway, we made use of dominant negative mutants of the p44
MAPK enzyme which can interfere with the activity of the
endogenous enzyme (23). In these experiments, two different
dominant negative forms of p44 MAPK specifically inhibited the
activation of the Bcl-2 promoter by NGF (Fig. 4b). A similar
effect was also observed with a dominant negative form of the
MEK-1 enzyme which is the upstream activator of the p42/p44
MAPK enzyme but was not observed with the protein kinase A
inhibitor (PKI) which binds with high affinity to the active
subunit of PKA and inhibits its activity (35) (Fig. 4b). It is known
that the small G protein Rap-1 is required for NGF-induced
sustained activation of MAP kinase (36). To test whether such
sustained activation was required for Bcl-2 promoter activation
by NGF, we overexpressed a dominant negative mutant of Rap-1
(N-17 Rap-1; 36) in PC12 cells. As shown in Figure 4b, this
mutant blocked the NGF-mediated activation of the Bcl-2
promoter indicating the involvement of Rap-1 in this effect.
Hence, inhibition of the p42/p44 MAPK pathway either with
a chemical inhibitor or with dominant negative forms of the
enzymes or a G-protein in this pathway greatly reduces inducibility
of the Bcl-2 promoter by NGF indicating that this pathway is
likely to be critical for such activation. To confirm that
constitutive activation of the p42/p44 pathway could mediate the
activation of the Bcl-2 promoter, we transfected our Bcl-2
promoter construct with a constitutively active mutant (SS/DD)
of the MEK-1 enzyme (37) which is the upstream activator of
p42/p44 MAPK enzymes. In this experiment (Fig. 4c) this
constitutively active MEK-1 was able to strongly activate the
Bcl-2 promoter. In contrast, constitutively active forms of protein
kinase A and protein kinase C (38) were unable to activate the
Bcl-2 promoter. Hence protein kinase A cannot activate the Bcl-2
promoter in PC12 cells in accordance with its lack of activation
by cyclic AMP (see above) whilst a similar lack of inducibility
occurs for protein kinase C, although this enzyme is responsible
for the phosphorylation of CREB protein in B cells allowing it to
activate the Bcl-2 promoter (20). Taken together, therefore, these
findings indicate that the PKA, PKC and p38MAPK pathways are
not involved in the activation of the Bcl-2 promoter by NGF
which is, however, dependent upon the p42/p44 MAPK pathway.
DISCUSSION
Several previous studies (17–21) have defined different regions
of the predominant P1 Bcl-2 promoter which can mediate its
responses to various stimuli and differentiation events in
non-neuronal cells such as B lymphocytes. In previous studies in
neuronal cells (21,22) we showed that the neuronally-expressed
POU family transcription factor Brn-3a is able to activate the
Bcl-2 P2 promoter via a sequence located between bases –584
and –594 upstream of the translational start site. Here we show,
however, that a distinct region located between bases –1472 and
–1414 upstream of the translational start site is critical for the
NGF responsiveness of the Bcl-2 P1 promoter. Hence, at least two
distinct regions of the promoter are involved in its regulation in
neuronal cells mediating the response to NGF and to the POU
family transcription factor, Brn-3a, respectively.
Although the region mediating the response to NGF which we
have defined is distinct from these other regulatory regions, it
does contain a sequence which has previously been shown to bind
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Figure 4. Role of different signalling pathways in the activation of the Bcl-2 promoter by NGF. (a) Effect of the p42/p44 MAPK inhibitor PD098059 (at a final
concentration of 50 mM) and the p38 MAPK inhibitor SB203580 (at a final concentration of 10 mM) on the response of the full-length Bcl-2 promoter to NGF. The
effect of the two inhibitors on the activity of the promoter is shown both in the presence and absence of NGF. (b) Effect on the NGF response of co-transfecting the
full-length Bcl-2 promoter with dominant negative mutants of p42/p44 MAPK (TA and YF), MEK-1 (D-N) or Rap-1 (N17) or with a PKA inhibitor (PKI). In each
case, promoter activity is shown in the absence (open bar) or the presence (solid bar) of NGF. (c) Response of the Bcl-2 promoter in the absence of NGF to
co-transfection with constitutively active mutants of MEK-1 (SS/DD), PKA or PKC. All values are the mean of five experiments whose standard error is shown by
the bars.
ab c
binding site for WT1 within the Bcl-2 promoter was shown to be
occupied on the inactive silent allele of Bcl-2 and to be
unoccupied on the active translocated allele. The implication of
this finding (that WT1 binding to this site represses Bcl-2 gene
expression) was supported by transfection studies in which a
WT1 expression vector was able to repress the Bcl-2 promoter
when its binding site was intact but not when it was mutated (29).
Although the NGF-induced transcription factors NGFI-A and
NGFI-C are members of the same transcription factor family as
WT1 and bind to similar sites (30,31), we have been unable to
detect an NGF-inducible protein which binds to this site in the
Bcl-2 promoter (data not shown). In agreement with this,
overexpression of NGFI-A has previously been shown not to
activate the Bcl-2 promoter (29).
It is possible, therefore, that the NGF-mediated activation of the
Bcl-2 promoter is mediated via a post-translational modification
of a transcription factor which we have detected bound to this site
both prior to and after NGF treatment. Evidently, this post-
translational modification could neutralise the inhibitory activity
of a repressor protein or could result in the enhanced activating
ability of a previously inactive protein. More detailed analysis
and mutagenesis of this region will be necessary to determine the
role of the WT1 binding site and/or other putative binding sites
in this region, in mediating the effect of NGF on the Bcl-2
promoter.
These considerations draw attention to the signalling pathways
by which NGF mediates its effect upon the Bcl-2 promoter. It has
previously been shown that NGF treatment of PC12 cells
activates several different signal transduction pathways including
protein kinase C (39), protein kinase A (40) and the Ras-dependent
mitogen-activated protein kinases (41). Here we have shown by
a combination of chemical inhibitors and mutant forms of various
kinase enzymes that neither PKC, PKA or p38MAPK enzymes
are apparently involved in the stimulation of the Bcl-2 promoter
by NGF. In contrast, such stimulation can be inhibited by both a
chemical inhibitor of the p42/p44 MAPK enzymes as well as by
dominant negative forms of these enzymes and Bcl-2 gene
expression can be stimulated by a constitutively active form of the
MEK-1 enzyme which is the upstream activator of the
p42/p44MAPK enzymes. These experiments thus establish the
requirement for this p42/p44 MAPK pathway in the activation of
the Bcl-2 promoter by NGF.
Using a similar approach, it has previously been shown that this
pathway is also required for the NGF-induced differentiation of
PC12 cells (41). Similarly, we have previously shown that the
transcriptional activating ability of the CBP co-activator is
directly stimulated by NGF in PC12 cells and this effect depends
upon the p42/p44MAPK pathway (42). Thus, if CBP is recruited
to DNA by linkage to the DNA binding domain of a heterologous
transcription factor, its ability to stimulate transcription from
promoters containing binding sites for this factor is enhanced by
NGF in a p42/p44 MAPK-dependent manner (42). Moreover, we
have recently shown that CBP and the p42/p44MAPK enzymes
specifically associate with one another and can be co-immuno-
precipitated (43).
It is possible, therefore, that the transcription factor which
activates Bcl-2 expression following NGF treatment uses CBP as
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Although CBP was originally defined as a co-activator binding to
the phosphorylated form of the CREB factor, it is unlikely that
CREB is involved in the responses we have observed, since the
CRE binding site for CREB is not involved in the response to
NGF and the promoter itself does not respond to cyclic AMP
treatment of PC12 cells.
Further analysis of the transcription factor(s) involved in the
activation of the Bcl-2 promoter by NGF will be required in order
to determine the manner in which the promoter is activated via the
p42/p44 MAPK pathway. It is already clear, however, that NGF
can directly activate the Bcl-2 promoter paralleling its previously
described ability to stimulate Bcl-2 protein synthesis in PC12
cells (14) and that this effect is dependent on the p42/p44 MAPK
pathway rather than upon other NGF activated pathways such as
those involving PKC, PKA or the p38MAPK pathway.
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